Epidemiological Context and Rationale
- India harbors approximately 40 to 50 million individuals with Chronic Hepatitis B (CHB).
- Perinatal and early childhood transmission accounts for 70% to 80% of chronic cases.
- Without intervention, 90% of perinatally infected infants develop chronicity, compared to less than 5% in adults.
- Left untreated, 15% to 40% progress to cirrhosis or hepatocellular carcinoma (HCC) by adulthood.
Pharmacological Arsenal
- Treatment relies on high-barrier nucleos(t)ide analogues (NAs).
- Long-term NA therapy achieves viral suppression exceeding 95%, reduces HCC risk by 50% to 70%, and improves hepatic histology.
- Preferred Agents in Pediatrics: Entecavir (ETV) is approved for children $\ge$ 2 years; Tenofovir Alafenamide (TAF) is approved for adolescents $\ge$ 12 years.
- TAF demonstrates superiority over Tenofovir Disoproxil Fumarate (TDF) regarding bone mineral density (osteoporosis) and renal safety (chronic kidney disease).
Global and National Guideline Updates (2024-2026)
| Issuing Body | Key Diagnostic and Treatment Recommendations |
|---|---|
| WHO 2024 | Expanded eligibility for all adolescents $\ge$ 12 years with HBV DNA >2000 IU/mL + ALT >Upper Limit of Normal (ULN) on two occasions, or presence of cirrhosis regardless of ALT/DNA. |
| AASLD/IDSA 2025 | Advocates selective treatment of the immune-tolerant phase. Recommends therapy if age >40 years or significant fibrosis ($\ge$ F2) or inflammation ($\ge$ G2). Shared decision-making for <40 years. |
| EASL 2025 | Treat HBeAg+ chronic infection if HCC risk or extrahepatic manifestations exist. Advanced fibrosis (LSM $\ge$ 8 kPa) mandates treatment regardless of ALT/DNA levels. |
| INASL 2025 | Prioritizes TAF/ETV/TDF as first-line. Recommends individualized management and emphasizes long-term adherence in pediatric populations. |
Prevention of Mother-to-Child Transmission (PMTCT)
- Universal Hepatitis B birth dose and subsequent pentavalent vaccine remain the cornerstone of primary prevention.
- Maternal prophylaxis using TDF or TAF initiated at 28 weeks of gestation is indicated if maternal HBV DNA exceeds 200,000 IU/mL.
- This intervention effectively reduces the risk of vertical transmission to less than 1%.
Diagnostic Monitoring and Indian Public Health Integration
- Invasive liver biopsy has been largely replaced by non-invasive tools such as FibroScan (Vibration-Controlled Transient Elastography), APRI, and FIB-4 scores for fibrosis assessment.
- Routine monitoring requires ALT and HBV DNA evaluation every 6 to 12 months.
- The National Viral Hepatitis Control Programme (NVHCP) provides free diagnostics, reflex HBV DNA testing, and NA treatment (prioritizing TDF and ETV) at designated centers, aiming for a 90% reduction in new infections by 2030.